T1	Participants 52 72	uremic pericarditis.
T2	Participants 207 368	24 patients with endstage chronic renal failure and pericarditis randomly received indomethacin, 25 mg four times daily, (11 patients) or a placebo (13 patients)
T3	Participants 394 461	patients received peritoneal or hemodialysis treatment concurrently
